%0 Journal Article
%A Garcia, J L
%A Lozano, R
%A Misiewicz-Krzeminska, I
%A Fernandez-Mateos, J
%A Krzeminski, P
%A Alfonso, S
%A Marcos, R A
%A Garcia, R
%A Gomez-Veiga, F
%A Virseda, A
%A Herrero, M
%A Olmos, D
%A Cruz-Hernandez, J J
%T A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
%D 2017
%U http://hdl.handle.net/10668/11290
%X Androgen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p  Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
%K AR-V7
%K Androgen receptor
%K CD133
%K Capillary nano-immunoassay
%K Circulating tumor cells
%K PTEN
%~